Zentiva's Nevolat to Revolutionize EU Weight Loss Market with Cheaper Liraglutid
The pharmaceutical landscape is set to change with the expiration of patent protection for Liraglutid in weight loss treatments across the EU. Zentiva is poised to launch Nevolat, a generic version of the medication, aiming to make weight loss injections more affordable and accessible.
The current list price for the original Liraglutid weight loss medication, Saxenda, in Germany stands at around €291 for a pack of five pens. Zentiva's Nevolat, the first generic Liraglutid product to hit the market, promises significant price reductions of 50 to 70 percent.
While Liraglutid is considered less effective than newer weight loss medications, the availability of a cheaper generic alternative could increase access to treatment for many. The impact on the market and the price of Nevolat will depend on Novo Nordisk's response and competition from other generic manufacturers.
Zentiva's Nevolat, launching in the coming weeks, will offer a more affordable option for weight loss treatment. With its reduced price, Nevolat could make a significant difference in accessibility, despite Liraglutid's relative effectiveness compared to newer medications.
